What is Exicure Inc?
Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 7.07M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.